Cytodyn Inc (CYDY)

[woodenbear]

I also agree with BD. But I think it is more than likely they will over enroll considering they have in the past and it really is the prudent thing to do w such a small sample size. With that said, timelines are impossible to predict bc we don’t know how many they wish to enroll, how many are already enrolled, or the rate of enrollment. Management says PE by end of 1Q. So that’s the next milestone. However I wouldn’t get my hopes up too much given past deadlines.

I don’t believe they need FDA permission to unblind but will likely seek it anyways for the reasons BD mentioned.